Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.

Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA

Open source

DOI: 10.1177/13524585251382796
Published: 2025 Nov
Container: Multiple sclerosis (Houndmills, Basingstoke, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/13524585251382796,
  title = {Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.},
  author = {Selmaj KW and Steinman L and Comi G and Bar-Or A and Arnold DL and Hartung HP and Montalbán X and Havrdová EK and Sheffield JK and Krakovich A and Cheng CY and Riolo JV and Pachai C and Thorpe A and DeBoer E and Kappos L and Cohen JA and Cree BA},
  year = {2025},
  journal = {Multiple sclerosis (Houndmills, Basingstoke, England)},
  doi = {10.1177/13524585251382796},
  url = {https://doi.org/10.1177/13524585251382796}
}

RIS

TY  - JOUR
TI  - Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
AU  - Selmaj KW
AU  - Steinman L
AU  - Comi G
AU  - Bar-Or A
AU  - Arnold DL
AU  - Hartung HP
AU  - Montalbán X
AU  - Havrdová EK
AU  - Sheffield JK
AU  - Krakovich A
AU  - Cheng CY
AU  - Riolo JV
AU  - Pachai C
AU  - Thorpe A
AU  - DeBoer E
AU  - Kappos L
AU  - Cohen JA
AU  - Cree BA
PY  - 2025
JO  - Multiple sclerosis (Houndmills, Basingstoke, England)
DO  - 10.1177/13524585251382796
UR  - https://doi.org/10.1177/13524585251382796
ER  -

APA

KW, S., L, S., G, C., A, B., DL, A., HP, H., X, M., EK, H., JK, S., A, K., CY, C., JV, R., C, P., A, T., E, D., L, K., JA, C., & BA, C. (2025). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.. Multiple sclerosis (Houndmills, Basingstoke, England). https://doi.org/10.1177/13524585251382796

Source records

pubmed · retrieved 2026-09-26T11:15:21.391Z
europe-pmc · retrieved 2026-09-26T11:15:21.405Z